AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31679621
Drug: Everolimus-eluting cobalt-chromium
RxNorm normalized name: Cobalt
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus-eluting cobalt-chromium stents (Co-Cr EESs) with 3 months of dual antiplatelet therapy
Trial: 25480994
Drug: Xience V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xience V drug-eluting stent (DES; n = 48)
Trial: 25480994
Drug: Bare-metal stent
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bare-metal stent (BMS) postdilated with the SeQuent Please drug-eluting balloon (DEB; n = 41)
Trial: 22424833
Drug: Intraocular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular injections of bevacizumab every 6 weeks for 6 months
Trial: 22424833
Drug: Intraocular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular injections of bevacizumab
Trial: 18087554
Drug: Felodipine controlled
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine controlled release tablets with Hydrochlorothiazide
Trial: 18087554
Drug: Felodipine controlled
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine controlled release tablets with Metoprolol
Trial: 18087554
Drug: Felodipine controlled
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine controlled release tablets with Lisinopril
Trial: 18087554
Drug: Felodipine controlled
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine controlled release tablets alone
Trial: 18087554
Drug: Felodipine controlled
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine controlled release tablets
Trial: 16041734
Drug: Chi‐Ju‐Di‐Huang‐Wan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chi‐Ju‐Di‐Huang‐Wan with topical eye drops
Trial: 16041734
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with topical eye drops
Trial: 11981646
Drug: NaCl solutions
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaCl solutions of different osmolarities (0‐1200 mosmol/l)
Trial: 7648940
Drug: Cisapride 5mg
RxNorm normalized name: CISAPRIDE 5MG/5ML SUSP,ORAL
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride 5mg three times daily for 4 weeks
Trial: 2655526
Drug: Naproxen (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (in addition to amoxicillin)
Trial: 2655526
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in addition to amoxicillin)
Trial: 26028962
Drug: Tbo-filgrastim (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tbo-filgrastim (5 μg/kg intravenous infusion)
Trial: 26028962
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg oral dose)
Trial: 15917194
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous infusion)
Trial: 23522488
Drug: 16 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/m2 sagopilone over 3 h (treatment arm A)
Trial: 23522488
Drug: 22 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg/m2 sagopilone over 0.5 h (treatment arm B)
Trial: 23522488
Drug: 22 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg/m2 sagopilone over 3 h (treatment arm C)
Trial: 16731406
Drug: Etodolac, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac, 600 mg, single dose preoperatively and 2 single doses of 600 mg on days 1 and 2 postoperatively
Trial: 16731406
Drug: Dexamethasone, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 8 mg single dose preoperatively and 2 single doses of 4 mg on days 1 and 2 postoperatively
Trial: 16285227
Drug: Combined-modality approaches
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality approaches with chemotherapy; specific agents not detailed; duration not specified.
Trial: 16285227
Drug: Systemic multiagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic multiagent chemotherapy for metastatic disease; specific agents not detailed; duration not specified.
Trial: 16285227
Drug: Newer cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer cytotoxic drugs and biologically targeted agents; specific agents not detailed; duration not specified.
Trial: 9208572
Drug: Parenteral Nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Nutrition (PN, without glutamine)
Trial: 6768376
Drug: Pentazocine 45
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentazocine 45 mg
Trial: 6768376
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of pethidine
Trial: 6768376
Drug: Pentazocine (more
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (more than one injection)
Trial: 30806186
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy in Bcl-2 negative patients
Trial: 30806186
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy in Bcl-2 positive patients
Trial: 30806186
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy in Bcl-2 positive patients
Trial: 21058480
Drug: Quick meridian
RxNorm normalized name: Cal-Quick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quick meridian needling therapy plus scalp acupuncture (group A)
Trial: 17542201
Drug: Powered toothbrush
RxNorm normalized name: Pro Clean Spinbrush Powered Toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powered toothbrush (Braun Oral‐B 3D Excel)
Trial: 17542201
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral‐B 35)
Trial: 15860385
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pravastatin daily (group A, n = 20)
Trial: 9790003
Drug: Midazolam (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.35 mg/kg) and ketamine (5 mg/kg) (Group A)
Trial: 9790003
Drug: Trimeprazine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimeprazine (3 mg/kg) and methadone (0.2 mg/kg) (Group B)
Trial: 2551537
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Fragmin) for 5-10 days
Trial: 2551537
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (continuous intravenous heparin)
Trial: 3091459
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Fragmin)
Trial: 31129183
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg zinc gluconate daily for 8 weeks)
Trial: 19581455
Drug: IV doripenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV doripenem at 500 mg every 8 hours (q8h)
Trial: 19581455
Drug: IV levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV levofloxacin at 250 mg every 24 hours (q24h)
Trial: 11772847
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg intravenously)
Trial: 9445204
Drug: Maximum dose
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum dose of acetazolamide (Diamox)
Trial: 9445204
Drug: Small doses
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small doses of acetazolamide added to dorzolamide treatment
Trial: 8010458
Drug: Demand dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand dose PCEA (3 mL; lockout interval = 10 min)
Trial: 8010458
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion plus demand dose PCEA (3 mL/h and 6 mL/h)
Trial: 8010458
Drug: Fixed-rate continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-rate continuous epidural infusion (CEI) at 12 mL/h
Trial: 8010458
Drug: All PCEA
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All PCEA groups (including demand dose and continuous infusion)
Trial: 8010458
Drug: PCEA groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA groups receiving no background infusion or a 3-mL/h background infusion
Trial: 2644828
Drug: Nifedipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (60 to 90 mg per day)
Trial: 6366561
Drug: Propranolol (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (240 mg per day)
Trial: 31860911
Drug: Pink-neck implant
RxNorm normalized name: chlorhexidine acetate Topical Solution [Steripod Pink]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pink-neck implant and abutment
Trial: 31860911
Drug: Gray implant
RxNorm normalized name: gray birch pollen extract
DrugBank: Betula populifolia pollen (DB10724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gray implant and abutment (control)
Trial: 28840583
Drug: G‐CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (5 μg/kg/day, for 6 consecutive days) in addition to standard medical therapy with antiviral drugs
Trial: 28840583
Drug: Antiviral drugs
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs alone
Trial: 25573908
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil plus pulse oral dexamethasone
Trial: 18537470
Drug: High Protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Protein Group (protein drink with additional protein and ginger twice daily)
Trial: 18537470
Drug: Protein Group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein Group (protein drink and ginger twice daily)
Trial: 15695544
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural local anaesthetic and steroid treatment
Trial: 15695544
Drug: Targeted epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted epidural local anaesthetic and steroid placement with spinal endoscope
Trial: 9895342
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine therapy (11, 22, and 44 mg daily)
Trial: 7769051
Drug: Nafarelin 200
RxNorm normalized name: nafarelin 200 MCG/ACTUAT Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin 200 micrograms twice daily
Trial: 7769051
Drug: Buserelin 200
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin 200 micrograms five times daily
Trial: 7769051
Drug: Nafarelin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin 400 micrograms twice daily
Trial: 7769051
Drug: Nafarelin (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin (either dose)
Trial: 282999
Drug: Sorbitol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (20 g of chocolate with sorbitol)
Trial: 282999
Drug: Sucrose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (20 g of chocolate with 40% sucrose)
Trial: 24094613
Drug: On-site group
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site group cognitive behavioral therapy (CBT) for depression
Trial: 24094613
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care residential treatment
Trial: 23739435
Drug: Cavinton (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavinton (25 mg intravenous during 10 days and then 10 mg 3 times daily during 3 months)
Trial: 18415093
Drug: Artesunate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (4 mg/kg)
Trial: 18415093
Drug: Amodiaquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (10 mg/kg)
Trial: 18415093
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Artesunate and Amodiaquine
Trial: 16192502
Drug: MV with
RxNorm normalized name: MV with iron,folic acid(=,>1 mg)calcium (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MV with Vt = 10 mL/kg
Trial: 16192502
Drug: MV with
RxNorm normalized name: MV with iron,folic acid(=,>1 mg)calcium (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MV with Vt = 5 mL/kg
Trial: 15669893
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg/day
Trial: 10856673
Drug: Vancomycin 1
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 g every 12 hours
Trial: 10856673
Drug: Vancomycin 1
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 g every 24 hours
Trial: 9118847
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving AED monotherapy
Trial: 9118847
Drug: Current AED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current AED therapy
Trial: 3541427
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (two doses: one at birth and another 2 months later, plus a booster at 12 months)
Trial: 3541427
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (booster dose at 12 months)
Trial: 3541427
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (two doses)
Trial: 29672897
Drug: PF-04965842 3
RxNorm normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04965842 3 mg
Trial: 29672897
Drug: PF-04965842 10
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-04965842 10 mg
Trial: 29672897
Drug: PF-04965842 30
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 30 mg
Trial: 29672897
Drug: PF-04965842 100
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 100 mg
Trial: 29672897
Drug: PF-04965842 200
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-04965842 200 mg
Trial: 29672897
Drug: PF-04965842 400
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 400 mg
Trial: 29672897
Drug: PF-04965842 800
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 800 mg
Trial: 29672897
Drug: PF-04965842 30
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 30 mg QD for 10 days
Trial: 29672897
Drug: PF-04965842 100
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 100 mg QD for 10 days
Trial: 29672897
Drug: PF-04965842 200
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-04965842 200 mg QD for 10 days
Trial: 29672897
Drug: PF-04965842 400
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 400 mg QD for 10 days
Trial: 29672897
Drug: PF-04965842 100
RxNorm normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-04965842 100 mg BID for 10 days
Trial: 29672897
Drug: PF-04965842 200
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-04965842 200 mg BID for 10 days
Trial: 26035523
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 to 450 mg/d)
Trial: 26995811
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) integrated with dental treatment
Trial: 26995811
Drug: Adapted dental
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted dental treatment
Trial: 15752945
Drug: Losartan low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Losartan low-dose (2.5/5.0 mg)
Trial: 15752945
Drug: Losartan middle-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan middle-dose (25/50 mg)
Trial: 15752945
Drug: Losartan high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan high-dose (50/100 mg)
Trial: 15752945
Drug: Switch from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from middle-dose losartan to placebo
Trial: 15752945
Drug: Switch from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from high-dose losartan to placebo
Trial: 15752945
Drug: Switch from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from low-dose losartan to placebo
Trial: 10375429
Drug: Elastoviscous 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastoviscous 0.1% Hylan A solution
Trial: 1464864
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acids (3.8 g of eicosapentaenoic acid plus 2.0 g of docosahexaenoic acid) and naproxen (750 mg/day for 16 weeks)
Trial: 1464864
Drug: corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corn oil (placebo omega-3 fatty acids, 7 g/day for 16 weeks) and naproxen (750 mg/day for 10 weeks followed by stepwise reduction)
Trial: 27854314
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (150 mg polyphenols)
Trial: 19130903
Drug: Uterosacral vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterosacral vaginal vault suspension
Trial: 15001605
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg daily (group 1)
Trial: 15001605
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg twice weekly (group 2)
Trial: 15001605
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily (group 3)
Trial: 12959308
Drug: Piroximone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroximone (0.5 mg kg(‐1); n = 10)
Trial: 12959308
Drug: Enoximone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (0.5 mg kg(‐1); n = 10)
Trial: 1107883
Drug: Propranolol 120
RxNorm normalized name: propranolol 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 120 mg daily
Trial: 2885116
Drug: Chlordesmethyldiazepam 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordesmethyldiazepam 2 mg daily
Trial: 25234550
Drug: 2-mg test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg test tablet
Trial: 9725476
Drug: Test tablet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test tablet
Trial: 23800419
Drug: Imipramine (targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (targeted dose adjusted to 200-300 ng/ml)
Trial: 23800419
Drug: Venlafaxine (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (high-dose, increased to 300-375 mg/day)
Trial: 18401987
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia using intravenous or inhaled anesthesia, maintenance with sevoflurane in oxygen and air at variable concentrations to maintain a bispectral index (BIS) between 40 and 60.
Trial: 19907420
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg of the ampakine CX717
Trial: 19907420
Drug: 1.6 mg
RxNorm normalized name: menthol 1.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg of naloxone
Trial: 16358864
Drug: Antibiotics (cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cefuroxime axetil, clarithromycin) and steroid (prednisone)
Trial: 16358864
Drug: Antibiotics (cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cefuroxime axetil, clarithromycin)